US 12,467,065 B2
Recombinant adeno-associated virus capsids with enhanced human pancreatic tropism
Katja Pekrun, Palo Alto, CA (US); and Mark A. Kay, Los Altos, CA (US)
Assigned to The Board of Trustees of the Leland Stanford Junior University, Stanford, CA (US)
Filed by The Board of Trustees of the Leland Stanford Junior University, Stanford, CA (US)
Filed on Dec. 6, 2022, as Appl. No. 18/062,333.
Application 18/062,333 is a division of application No. 16/370,735, filed on Mar. 29, 2019, granted, now 11,608,510.
Claims priority of provisional application 62/651,010, filed on Mar. 30, 2018.
Claims priority of provisional application 62/745,226, filed on Oct. 12, 2018.
Prior Publication US 2023/0304039 A1, Sep. 28, 2023
Int. Cl. C12N 15/86 (2006.01); A61K 47/69 (2017.01); C07K 14/00 (2006.01); C07K 14/005 (2006.01); C07K 14/015 (2006.01); C07K 14/075 (2006.01); C12N 15/10 (2006.01); C12N 7/00 (2006.01); C12N 15/90 (2006.01)
CPC C12N 15/86 (2013.01) [A61K 47/6901 (2017.08); C07K 14/015 (2013.01); C07K 14/075 (2013.01); C12N 15/102 (2013.01); C12N 7/00 (2013.01); C12N 15/902 (2013.01); C12N 2710/10041 (2013.01); C12N 2710/10071 (2013.01); C12N 2710/10134 (2013.01); C12N 2710/10141 (2013.01); C12N 2750/14123 (2013.01)] 2 Claims
 
1. A method of using an AAV capsid polypeptide to deliver a nucleic acid to a subject, the method comprising the step of administering to the subject an AAV vector whose genome comprises the nucleic acid,
wherein the AAV capsid polypeptide is part of a functional AAV capsid,
wherein the functional AAV capsid packages a nucleic acid sequence, and
wherein the AAV capsid polypeptide sequence has the amino acid sequence selected from the group consisting of AAV-10A1 (SEQ ID NO: 1), AAV-10A3 (SEQ ID NO:2), AAV-10A4 (SEQ ID NO:3), AAV-10A5 (SEQ ID NO:4), AAV-18A1 (SEQ ID NO:5), AAV-10B1 (SEQ ID NO:6), AAV-10B3 (SEQ ID NO:7), AAV-10B5 (SEQ ID NO:8), AAV-10B6 (SEQ ID NO:9), AAV-10B7 (SEQ ID NO:10), AAV-18B2 (SEQ ID NO:12), and AAV-18B3 (SEQ ID NO:13).